JP2009518441A - Ｃｄ４０結合剤の使用方法 - Google Patents

Ｃｄ４０結合剤の使用方法 Download PDF

Info

Publication number
JP2009518441A
JP2009518441A JP2008544586A JP2008544586A JP2009518441A JP 2009518441 A JP2009518441 A JP 2009518441A JP 2008544586 A JP2008544586 A JP 2008544586A JP 2008544586 A JP2008544586 A JP 2008544586A JP 2009518441 A JP2009518441 A JP 2009518441A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
variable domain
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008544586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518441A5 (enExample
Inventor
ドラクマン，ジョナサン
ロウ，チェ−レオン
ルイス，ティム
Original Assignee
シアトル ジェネティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル ジェネティクス，インコーポレーテッド filed Critical シアトル ジェネティクス，インコーポレーテッド
Publication of JP2009518441A publication Critical patent/JP2009518441A/ja
Publication of JP2009518441A5 publication Critical patent/JP2009518441A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008544586A 2005-12-09 2006-12-11 Ｃｄ４０結合剤の使用方法 Pending JP2009518441A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74924605P 2005-12-09 2005-12-09
US81135306P 2006-06-05 2006-06-05
US81130106P 2006-06-05 2006-06-05
US84723406P 2006-09-25 2006-09-25
PCT/US2006/047308 WO2007075326A2 (en) 2005-12-09 2006-12-11 Methods of using cd40 binding agents

Publications (2)

Publication Number Publication Date
JP2009518441A true JP2009518441A (ja) 2009-05-07
JP2009518441A5 JP2009518441A5 (enExample) 2010-01-21

Family

ID=38218421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008544586A Pending JP2009518441A (ja) 2005-12-09 2006-12-11 Ｃｄ４０結合剤の使用方法

Country Status (11)

Country Link
US (1) US20090304687A1 (enExample)
EP (1) EP1968636A4 (enExample)
JP (1) JP2009518441A (enExample)
KR (1) KR20080079301A (enExample)
AU (1) AU2006329944A1 (enExample)
BR (1) BRPI0619586A2 (enExample)
CA (1) CA2632698A1 (enExample)
IL (1) IL191990A0 (enExample)
MX (1) MX2008007140A (enExample)
NO (1) NO20083002L (enExample)
WO (1) WO2007075326A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533853A (ja) * 2012-10-30 2015-11-26 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
RU2491095C2 (ru) * 2007-11-09 2013-08-27 Новартис Аг Применения анти-cd40-антител
AU2009206506B2 (en) * 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
WO2010121231A1 (en) 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CN107172880B (zh) 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
BR112017008959A2 (pt) 2014-10-29 2018-01-16 Seattle Genetics, Inc. método para tratamento de uma doença.
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022266496A1 (en) * 2021-06-17 2022-12-22 Parker Institute For Cancer Immunotherapy Methods of treating kras mutation subtypes with cd40 agonist
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
BRPI0509412A (pt) * 2004-04-16 2007-09-04 Genentech Inc método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
EP1747237A4 (en) * 2004-04-16 2008-05-21 Macrogenics Inc SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
JP5027804B2 (ja) * 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012017864; Ｈｕｓｓｅｉｎ　ＭＡ，　ｅｔ　ａｌ．: 'Ａ　ｐｈａｓｅ　Ｉ　ｈｕｍａｎｉｚｅｄ　ａｎｔｉ-ＣＤ４０　ｍｏｎｏｃｌｏｎａｌ　ａｎｔｉｂｏｄｙ　（ＳＧＮ-４０）　ｉｎ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ｍｕｌｔｉｐｌｅ　ｍｙｅｌｏｍａ' Ｂｌｏｏｄ Ｖｏｌ．１０６，　Ｎｏ．１１, 20051116, ｐ．７２３ａ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533853A (ja) * 2012-10-30 2015-11-26 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
JP2022191360A (ja) * 2012-10-30 2022-12-27 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
JP7482184B2 (ja) 2012-10-30 2024-05-13 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
JP2024096245A (ja) * 2012-10-30 2024-07-12 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
JP7698352B2 (ja) 2012-10-30 2025-06-25 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法

Also Published As

Publication number Publication date
US20090304687A1 (en) 2009-12-10
MX2008007140A (es) 2009-03-04
BRPI0619586A2 (pt) 2018-08-28
EP1968636A4 (en) 2010-06-02
CA2632698A1 (en) 2007-07-05
IL191990A0 (en) 2008-12-29
NO20083002L (no) 2008-08-14
EP1968636A2 (en) 2008-09-17
AU2006329944A1 (en) 2007-07-05
WO2007075326A3 (en) 2008-09-04
WO2007075326A2 (en) 2007-07-05
KR20080079301A (ko) 2008-08-29

Similar Documents

Publication Publication Date Title
US20090304687A1 (en) Methods of using cd40 binding agents
JP7641323B2 (ja) 治療抗体およびその使用
US20220153857A1 (en) Anti-cd40 antibodies
US11279764B2 (en) Antibodies specific for epidermal growth factor receptor variant III and their uses
US8492531B2 (en) Nucleic acids encoding humanized anti-CD40 antibodies
RU2313368C2 (ru) Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств
JP4679035B2 (ja) 併用療法
JP5122441B2 (ja) ヒト化抗ｃｄ７０結合剤およびその使用
CN112334195A (zh) 用于治疗自身免疫性疾病的抗cd40抗体
JP2023542678A (ja) 炎症状態の処置のための抗ｃｄ４０抗体の使用。
WO2024050031A2 (en) Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads
CN116782931A (zh) 抗cd40抗体用于治疗炎症性病况的用途
HK40017145A (en) Anti-gitr antibodies and methods of use thereof
HK1239706B (en) Anti-cd40 antibodies
HK1178176A (zh) 抗-cd40抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121023